12/30
04:30 pm
fblg
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
High
Report
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
12/30
02:12 pm
fblg
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
Low
Report
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
12/27
08:10 am
fblg
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
Medium
Report
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
12/23
07:55 am
fblg
FibroBiologics Announces $25 Million Financing
Medium
Report
FibroBiologics Announces $25 Million Financing
12/12
08:26 am
fblg
FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $12.00 price target on the stock.
High
Report
FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $12.00 price target on the stock.
11/25
08:32 am
fblg
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
Medium
Report
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
11/19
09:15 am
fblg
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
Medium
Report
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
11/14
09:15 am
fblg
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
High
Report
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
11/13
08:05 am
fblg
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/12
04:32 pm
fblg
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:20 pm
fblg
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/30
07:27 am
fblg
FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $12.00 price target on the stock.
Medium
Report
FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $12.00 price target on the stock.
10/29
09:15 am
fblg
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
Low
Report
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
10/28
09:31 am
fblg
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
Low
Report
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
10/18
08:30 am
fblg
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
Medium
Report
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
10/16
09:15 am
fblg
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
Medium
Report
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
10/11
09:31 am
fblg
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
High
Report
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit